Abstract: The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
Type:
Application
Filed:
August 15, 2023
Publication date:
April 4, 2024
Applicant:
SEAGEN INC.
Inventors:
Django Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
Abstract: Compounds and compositions are disclosed in which a Drug Unit is linked to a targeting Ligand Unit through a self-stabilizing Linker Unit from which a drug compound or active drug moiety is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease using the compounds and compositions of the invention are also disclosed.
Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.
Type:
Grant
Filed:
February 28, 2018
Date of Patent:
March 26, 2024
Assignee:
SEAGEN INC.
Inventors:
Andrew Waight, Chris Leiske, Travis Biechele, Django Sussman, Patrick Burke, Jocelyn Leiske
Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
March 19, 2024
Assignee:
Seagen Inc.
Inventors:
Christopher Scott Neumann, Kathleen Olivas, Robert Lyon, Kung-Pern Wang
Abstract: The present invention provides variant target binding agents and methods relating to the use of such binding agents for the prophylaxis or treatment of cancers and immunological disorders. The variant target binding agent is conjugated to a therapeutic agent that exerts a cytotoxic, cytostatic, or immunomodulatory effect on target cells.
Abstract: Provided are novel anti-av?6 antibodies and antibody-drug conjugates and methods of using such anti-av?6 antibodies and antibody-drug conjugates to treat cancer.
Type:
Application
Filed:
October 18, 2023
Publication date:
March 7, 2024
Applicant:
SEAGEN INC.
Inventors:
Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.
Type:
Application
Filed:
March 10, 2023
Publication date:
February 8, 2024
Applicants:
AGENSYS, INC., SEAGEN INC.
Inventors:
Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
Abstract: Methods of producing T cells having reduced surface fucosylation and use thereof in adoptive cell therapy, in particular, in cancer treatment are provided.
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
February 6, 2024
Assignee:
Seagen Inc.
Inventors:
Nicole Okeley, Jessica Field, Shyra Gardai, Ryan Heiser
Abstract: Provided herein are methods of treating cancer with an anti-TIGIT antibody in combination with an anti-PD-1 antibody and/or an anti-PD-L1 antibody.
Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include monoclonal antibodies, derivatives, and fragments thereof as well as compositions and kits comprising them. In some embodiments, the present invention provides an antibody having a heavy chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 63 and having a light chain with an amino acid sequence comprising at least 95% sequence identity to SEQ ID NO: 64.
Type:
Application
Filed:
November 7, 2022
Publication date:
January 11, 2024
Applicant:
Seagen Inc.
Inventors:
Ana Paula Galvao da Silva, Julie DeSander, Jeffrey Behrens, Darius Ghaderi, Mai Zhang, Kristan Meetze
Abstract: Compositions and methods for treating ovarian cancer are provided. Methods include combined treatment with chemotherapeutic agents and anti-STn antibodies. Chemotherapy resistant ovarian cancer cells may be reduced. Chemotherapy resistant ovarian cancer cells may include cancer stem cells.
Type:
Application
Filed:
November 7, 2022
Publication date:
January 4, 2024
Applicants:
Seagen Inc., The General Hospital Corporation
Inventors:
David A. Eavarone, Jeffrey Behrens, Jillian M. Prendergast, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
Abstract: The present invention provides methods of testing anti-STn antibodies for their ability target cancer stem cells by isolating cancer stem cells from cultures, contacting them with anti-STn antibodies being tested, and measuring resulting cell viability.
Type:
Application
Filed:
November 7, 2022
Publication date:
January 4, 2024
Applicants:
Seagen Inc., The General Hospital Corporation
Inventors:
David A. Eavarone, Julie DeSander, Jeffrey Behrens, Bo R. Rueda, Rosemary Foster, Kristen D. Starbuck
Abstract: The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.
Type:
Application
Filed:
February 28, 2023
Publication date:
January 4, 2024
Applicant:
Seagen Inc.
Inventors:
Ana Paula Galvao da Silva, Mai Zhang, Darius Ghaderi, Julie DeSander, Jeffrey Behrens, Jillian M. Prendergast
Abstract: Methods of treating cancer are provided that include administering glycan-interacting antibodies. Included are anti-sialyl Tn antigen antibodies and related compositions and formulations suitable to achieve desirable bioactivity, bioavailability, and toxicity levels.
Type:
Application
Filed:
November 7, 2022
Publication date:
January 4, 2024
Applicant:
Seagen Inc.
Inventors:
Daniel T. Dransfield, Jillian M. Prendergast, David A. Eavarone
Abstract: Ligand Drug Conjugates of hydrophobically-modified auristatin F compounds that exhibit cytotoxic activities towards targeted cells, including abnormal cells such as cancer cells, that are MDR+ while also exhibiting bystander activities towards nearby cells having lower expression of the moeity targeted by the Conjugate.
Abstract: The present invention provides improved processes for the preparation of auristatin drug-linkers with a PEG unit, as well as intermediates thereof.
Type:
Grant
Filed:
March 24, 2017
Date of Patent:
December 19, 2023
Assignee:
Seagen Inc.
Inventors:
Yunyu Mao, Philip Moquist, Anusuya Choudhury, Wendel Doubleday
Abstract: Provided are novel anti-?v?6 antibodies and antibody-drug conjugates and methods of using such anti-?v?6 antibodies and antibody-drug conjugates to treat cancer.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
November 28, 2023
Assignee:
Seagen Inc.
Inventors:
Maureen Ryan, Lori Westendorf, Eric Bradley Meyer, Heather Jean Kostner
Abstract: The invention provides methods of treating cancer, such as myeloid malignancies including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), with nonfucosylated anti-CD70 antibodies.